Venus Remedies, a research based pharmaceutical company, shares gained on Monday after it has entered into a distribution-cum-outlicensing agreement with Mylan for marketing its generic broad-spectrum antibiotic, meropenem, in three European countries.

Shares of the comapny are trading at Rs 293.60, up Rs 17.9, or 6.49% at the Bombay Stock Exchange (BSE) on Monday at 11:07 a.m.

The scrip has touched an intra-day high of Rs 294.95 and low of Rs 275.45. The total volume of shares traded at the BSE is 90,653.